News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2024

22 February, 2024 Year-End report January-December 2023 News English Regulatory MAR Report Interim Yearend IR Optional

2023

10 November, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan News Corporate Action Other English Regulatory MAR IR Optional
8 November, 2023 Interim report Q3 2023 News English Regulatory MAR Report Interim Q3 IR Optional
1 November, 2023 Egetis’ Nomination Committee for the 2024 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
31 October, 2023 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
11 October, 2023 Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory LHFI IR Optional
22 August, 2023 Interim report Q2 2023 News English Regulatory MAR VPML Report Interim Q2 IR Optional
28 June, 2023 Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
31 May, 2023 Board director in Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
23 May, 2023 Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
27 April, 2023 Bulletin from Egetis Therapeutics’ Annual General Meeting 2023 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
26 April, 2023 Interim report January-March 2023 News English Regulatory MAR Report Interim Q1 IR Optional
30 March, 2023 Egetis comments on market rumors News Corporate Action M&A English Regulatory MAR IR Optional
28 March, 2023 Egetis Therapeutics’ 2022 annual report published News English Regulatory VPML Report Annual IR Optional
23 March, 2023 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
22 February, 2023 Year-end Report Q4 2022 News English Regulatory MAR Report Interim Yearend IR Optional
31 January, 2023 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
25 January, 2023 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 210 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer
24 January, 2023 Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 200 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer

2022

8 November, 2022 Interim report January-September 2022 News English Regulatory MAR Report Interim Q3 IR Optional
25 October, 2022 Egetis presents Nomination Committee for the 2023 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
19 August, 2022 Interim report Q2 2022 News English Regulatory MAR VPML Report Interim Q2 IR Optional
31 May, 2022 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com